The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Global Autoinjectors Market (3rd Edition), 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    January 2020

  • Pages
    680

  • View Count
    7695

Example Insights

Global Autoinjector Market (3rd Edition), 2020-2030-Context Global Autoinjector Market (3rd Edition), 2020-2030-List of Autoinjectors Global Autoinjector Market (3rd Edition), 2020-2030-Autoinjector combination Products Global Autoinjector Market (3rd Edition), 2020-2030-Product Competitiveness Analysis
Global Autoinjector Market (3rd Edition), 2020-2030-Patent Analysis Global Autoinjector Market (3rd Edition), 2020-2030-Global Autoinjector Devices Global Autoinjector Market (3rd Edition), 2020-2030-Brand Positioning Matrix 	Global Autoinjector Market (3rd Edition), 2020-2030-Pipeline
Global Autoinjector Market (3rd Edition), 2020-2030-Case Study Global Autoinjector Market (3rd Edition), 2020-2030-Market Forecast Global Autoinjector Market (3rd Edition), 2020-2030-Futuer Forecast  

 

Overview

More than 40% of the US population is estimated to be suffering from some form of a chronic health condition. According to the US National Health Council, over 75% of the nation’s healthcare expenditure is on the treatment of chronic diseases, such as diabetes. The major share of expenses incurred by patients living with a chronic disorder is driven by the frequent need to medicate, which may require repeated visits to hospitals / out-patient clinics. Over time, a variety of solutions enabling self-administration of injectable drugs have been developed and introduced into the market. In a relatively short time period, the self-injection devices market has grown into a prominent and promising segment within the pharmaceutical industry. Autoinjectors represent one such type of device that has witnessed increased adoption among patients, especially for the treatment of emergency situations, such as anaphylactic shocks. According to developers, such devices are relatively easier to use, compared to other parenteral drug delivery systems, and have integrated needle-safety features. In fact, autoinjectors have been proven to have resolved a number of injection-related tolerability issues faced by patients.

Over the years, several players have launched proprietary autoinjectors-based combination products for use across a variety of therapeutic areas. EpiPen® is one of the most popular and widely recognized autoinjectors (based on historical sales data) available in the market today. Examples of other autoinjector combination products approved in 2019 include, NUCALA Autoinjector (GlaxoSmithKline), Vyleesi™ Autoinjector (AMAG Pharmaceuticals® / Palatin Technologies), Fasenra® (AstraZeneca) and Teribone™ (Asahi Kasei Pharma). Autoinjectors are also considered to be a potential pharmaceutical life cycle management tool; they are used by many pharmaceutical players to expand marketing exclusivity periods of proprietary drugs. For example, lyophilized Enbrel® was reformulated for delivery via the SureClick® autoinjector; this granted the drug almost 11 additional years of patent protection. It is also worth highlighting that there are a number of efforts underway to improve the existing generation of autoinjectors. Incorporation of healthcare data acquisition and analysis features, addition of smart functions to deal with medication-related errors, and improved safety measures, are some of the upgrades that device developers claim to be in the process of developing. In this context, it is worth mentioning that, so far, over 4,600 patent applications have been filed for autoinjectors and affiliated products / technologies. We believe that such efforts are likely to drive growth in this market over the coming years.

Scope Of the Report

The ‘Global Autoinjectors Market (3rd Edition), 2020-2030’ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of autoinjectors over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:

  • An overview of the current market landscape of companies engaged in developing and / or manufacturing autoinjectors, providing information on the usability (disposable and reusable), type of primary drug container (cartridge, syringe and vial), volume of container, type of dose (fixed and variable), route of administration (intradermal, intramuscular and subcutaneous), actuation mechanism (automatic and manual) and feedback mechanism integrated in the device. It also provides details on the developers, highlighting their year of establishment, company size (small-sized, mid-sized and large), location of headquarters and location of manufacturing facilities
  • Information on companies that are developing drugs in combination with autoinjectors, featuring details on initial year of approval (for marketed products), phase of development, usability of the device, route of administration (intracavernous, intramuscular and subcutaneous), type of drug molecule (antibody, peptide, protein and small molecule), dose strength, therapeutic area and other approved dosage forms (for marketed products). In addition, the section provides details on the company, including year of establishment, company size and location of headquarters
  • A competitiveness analysis of various disposable and reusable autoinjectors, taking into consideration supplier power (based on year of establishment and company size) and key product specifications, such as route of administration, primary drug container used, injector actuation mechanism, type of dose and user friendliness of the product.
  • An in-depth analysis of the various patents that have been filed / granted related to autoinjectors, till August 2019, highlighting details on key parameters, such as type of patent, publication year, issuing authority, CPC classification, emerging focus areas and leading industry players (on the basis of number of patents). It also includes a detailed patent benchmarking and an insightful valuation analysis. 
  • A detailed brand positioning analysis of leading industry players (shortlisted on the basis of strength of product portfolio), highlighting the current perceptions regarding their proprietary brands by taking into consideration several relevant aspects, such as strength and diversity of product portfolio, route of administration, actuation mechanism, geographical presence / reach and supplier power of each company.
  • A list of marketed drugs / therapies and pipeline candidates that are likely to be developed in combination with autoinjectors in the near future, shortlisted on the basis of an in-depth analysis that takes into consideration various relevant parameters, such as route of administration, type of drug molecule, target indications, other available dosage forms (for approved drugs) and historical annual sales information (for approved drugs).
  • A list of key opinion leaders (KOLs) within this domain who were short-listed based on their contributions (such as involvement in clinical trials and being mentioned in patent applications); it features a schematic world map representation, highlighting the geographical locations of eminent scientists / researchers engaged in this domain. 
  • Detailed case studies on the most commonly targeted indications, covering history of development and detailed description of the approved autoinjector products, along with their respective mechanisms of action and historical sales records; the study provides a list of all the drugs that are currently being delivered via autoinjectors. 
  • A case study on the role of CMOs offering services for drug delivery devices; it features a list of service providers, highlighting the various types of services offered for different types of drug-delivery devices.  
  • A SWOT analysis capturing the key parameters and trends that are likely to influence the future of autoinjectors market.
  • Elaborate profiles of autoinjector manufacturers that have more than three devices in their respective product portfolios; each profile features an overview of the company, its financial information (if available), information on its product portfolio, autoinjector device specifications, collaborations, recent developments and an informed future outlook. Additionally, the report includes brief profiles of emerging players that have been established in the past decade.

One of the key objectives of the report was to estimate the existing market size and assess potential future growth opportunities for autoinjector devices. Based on parameters, such as number of commercialized combination products, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market over the period 2020-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] usability (disposable and reusable), [B] route of administration (subcutaneous and intramuscular), [C] type of molecule (monoclonal antibody, peptide, protein and small molecule) [D] therapeutic indication (anaphylaxis, multiple sclerosis, rheumatoid arthritis, migraine, diabetes and other indications), and [E] key geographies (North America, Europe, Asia-Pacific and rest of the World). 

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. The opinions and insights presented in the report were influenced by discussions held with several players in this industry. The study includes detailed transcripts of discussions held with the following individuals: 

  • David Daily (CEO and Co-founder, DALI Medical Devices) 
  • Dennis Lee (Senior Program Officer in CMC, Bill & Melinda Gates Foundation)
  • Douglas Marenzi (Managing Director, PHC Injection Technologies) 
  • Tsachi Shaked (Senior Marketing and BD Director, Injectable Drug Delivery Devices, Elcam Medical)
  • Jesse Fourt (Design Director, IDEO)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the autoinjectors market in the short-mid term and long term.

Chapter 3 provides a general overview of various devices that enable self-administration of drugs, specifically focusing on autoinjectors. The chapter features a discussion on the historical evolution of autoinjectors, along with details related to their individual components, device categories and associated manufacturing / packaging processes. In addition, it elaborates on the benefits of autoinjectors that have led to their growing adoption over the last several years. The chapter also highlights the existing concerns related to needlestick injuries and the various preventive laws that have been passed worldwide, for addressing the pressing need for introducing advanced safety features in such devices. 

Chapter 4 is an overview of the various types of primary drug containers that are utilized in autoinjectors. It features information on  current trends related to the use of prefilled syringes and cartridges. In addition, it lists the diverse types of primary drug containers that are available in the market, along with details on companies that are involved in the production of such containers. 

Chapter 5 provides information on close to 80 autoinjectors that have already been developed or are under development. It features a comprehensive analysis of these devices based on different parameters, such as primary drug container used (cartridge, prefilled syringe and vial), volume, device usability (disposable and reusable), route of administration (intramuscular, intradermal and subcutaneous) and other technical parameters. In addition, the chapter provides information on manufacturers, along with information on year of establishment, location of headquarters and strength of employee base.

Chapter 6 presents a product competitiveness analysis of disposable and reusable autoinjectors (separately) based on the supplier power and key product specifications, such as route of administration, primary drug container used, mechanism of operation, dosage type and user friendliness. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 7 provides an elaborate brand positioning analysis of the leading device developers / manufacturers, highlighting the current perceptions regarding their proprietary brands across different device types. The analysis takes into consideration several aspects, such as strength and diversity of product portfolio, routes of administration, actuation mechanism, geographical presence / reach and supplier power of each player.

Chapter 8 provides an in-depth patent analysis, presenting an overview of how the industry is evolving from the R&D perspective. For this analysis, we looked at the patents that have been published by various players since 2013. The analysis highlights the key information associated with these patents, including patent type, publication year, geographical location, CPC classification, emerging areas, leading industry players, patent benchmarking and valuation analysis. 

Chapter 9 provides details on the various pipeline and approved products that are being tested or available in autoinjectors. It features a detailed analysis of these drugs, based on the various parameters, such as the target therapeutic indication(s), phase of development, type of drug molecule, route of administration, approval year (in case of marketed products), dosage (in case of marketed products) and other approved dosage forms (in case of marketed products). In addition, the chapter provides information on drug developers, year of their establishment, location of headquarters and strength of employee base.  

Chapter 10 provides detailed case studies on the most commonly targeted indications covering history of development and detailed description of the approved autoinjector products, along with mechanism of action and historical sales of the drugs.

Chapter 11 presents a list of marketed and pipeline molecules that are likely to be considered for delivery via autoinjectors in the future. It is worth highlighting that this list has been compiled based on various parameters, such as route of administration, target therapeutic indication(s), other available dosage forms (in case of marketed drugs), type of drug molecule and drug sales of the approved product candidates. For the purpose of this analysis, we collated a list of over 100 top-selling marketed drugs, which were initially screened on the basis of route of administration (subcutaneous / intramuscular). Additionally, we reviewed over 1,400 clinical trials and compiled a list of pipeline molecules that are being investigated for delivery via the aforementioned routes. The likelihood of delivery via an autoinjector in the future was estimated using the weighted average method. 

Chapter 12 includes detailed profiles of key autoinjector manufacturers. Each profile features an overview of the company, its financial information (if available), information on its product portfolio, autoinjector device specifications, collaborations, recent developments and an informed future outlook.

Chapter 13 includes brief profiles of some of the emerging players in the autoinjectors industry. Each profile features an overview of the company, technology, information on its product portfolio, autoinjector device specifications and recent developments. 

Chapter 14 provides an analysis of KOLs in the field of drug-delivery devices, including autoinjectors. It features a comprehensive list of principal investigators / study directors of different clinical trials and patent assignees, along with the information related to the affiliated organizations. The chapter features a schematic representation on a world map, highlighting the geographical locations of eminent scientists / researchers who are engaged in this domain. It highlights the notable KOLs who have relatively more experience in this domain. The chapter also provides details on different parameters of the KOLs (wherever available), including number of publications, number of citations, number of clinical trials / patents, number of affiliations and extent of professional network.

Chapter 15 presents a detailed analysis capturing the key parameters and trends that are likely to influence the future of autoinjectors market, under a comprehensive SWOT framework. 

Chapter 16 is a case study focused on the role of medical device CMOs in the manufacturing and assembly of drug-delivery devices, including autoinjectors. It provides a list of service providers with details on their scale of operation and types of services provided for production of devices. 

Chapter 17 presents an insightful market forecast analysis, highlighting the future potential of the autoinjectors market till the year 2030. We have segregated the opportunity of the market on the basis of [A] usability (disposable and reusable), [B] route of administration (subcutaneous and intramuscular), [C] type of molecule (monoclonal antibody, peptide, protein and small molecule) [D] therapeutic indication (anaphylaxis, multiple sclerosis, rheumatoid arthritis, migraine, diabetes and other indications), and [E] key geographies (North America, Europe, Asia-Pacific and rest of the World). The likely size of the market has been estimated both in terms of value (USD billion) and volume (number of devices). 

Chapter 18 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 19 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with David Daily (CEO and Co-founder, DALI Medical Devices), Dennis Lee (Senior Program Officer in CMC, Bill & Melinda Gates Foundation), Douglas Marenzi (Managing Director, PHC Injection Technologies), Tsachi Shaked (Senior Marketing and BD Director, Injectable Drug Delivery Devices, Elcam Medical) and Jesse Fourt (Design Director, IDEO).

Chapter 20 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 21 is an appendix, which provides a list of companies and organizations mentioned in this report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Drug Delivery Systems
3.3. Drawbacks of Conventional Parenteral Delivery Systems
3.4. Needlestick Injuries
3.4.1. Incidence and Cost Burden
3.4.2. Prevention
3.4.2.1. Government Legislation for the Prevention of Needlestick Injuries

3.5. Emerging Trend of Self-Administration
3.5.1. Rising Burden of Chronic Diseases
3.5.2. Healthcare Cost Savings
3.5.3. Need for Immediate Treatment in Emergency Situations
3.5.4. Growth of Injectable Biologics Market
3.5.5. Addressing Key User Safety Requirements

3.6. Types of Self- Administration Devices
3.6.1. Prefilled Syringes
3.6.2. Pen-Injectors
3.6.3. Needle-Free Injectors
3.6.4. Autoinjectors
3.6.5. Large Volume Wearable Injectors

3.7. Overview of Autoinjectors
3.7.1. Components of Autoinjectors
3.7.2. Classification of Autoinjectors
3.7.2.1. On the Basis of Mechanism of Action
3.7.2.2. On the Basis of Usability
3.7.2.3. On the Basis of Type of Dose
3.7.3. Manufacturing / Packaging of Autoinjectors
3.7.4. Benefits of Autoinjectors

3.8. Regulatory Considerations
3.8.1. Medical Devices
3.8.2. Drug Device Combination Products

3.9. Future Perspectives

4. PRIMARY DRUG CONTAINERS
4.1. Chapter Overview
4.2. Types of Packaging
4.3. Introduction to Primary Drug Containers
4.3.1. Role of Primary Drug Containers
4.3.2. Types of Primary Drug Containers
4.3.2.1. Cartridges
4.3.2.1.1. Components of Cartridges
4.3.2.1.2. Types of Cartridges
4.3.2.1.2.1. Single Chamber Cartridge
4.3.2.1.2.2. Dual Chamber Cartridge
4.3.2.1.3. Cartridges Available in the Market

4.3.2.2. Syringes
4.3.2.2.1. Components
4.3.2.2.2. Types of Syringes
4.3.2.2.2.1. Based on Number of Chambers
4.3.2.2.2.2. Based on Type of Needle
4.3.2.2.3. Prefilled Syringe Systems Available in the Market
4.3.2.2.3.1. Glass Prefilled Syringes
4.3.2.2.3.2. Plastic Prefilled Syringes

4.3.2.3. Vials
4.3.2.3.1. Components
4.3.2.3.2. Vials Available in the Market

4.4. Comparison of Fabrication Materials

5. AUTOINJECTORS: CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Autoinjectors: List of Devices
5.2.1. Analysis by Usability
5.2.2. Analysis by Type of Primary Container
5.2.3. Analysis by Volume of Container
5.2.4. Analysis by Type of Dose
5.2.5. Analysis by Route of Administration
5.2.6. Analysis by Actuation Mechanism
5.2.7. Analysis by Type of Feedback Mechanism

5.3. Autoinjectors: List of Developers
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Geographical Location of Headquarters
5.3.4. Analysis by Geographical Location of Manufacturing Facilities

6. PRODUCT COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Assumptions and Key Parameters
6.4. Product Competitiveness Analysis
6.4.1. Disposable Autoinjectors
6.4.2. Reusable Autoinjectors

7. BRAND POSITIONING ANALYSIS OF KEY INDUSTRY PLAYERS
7.1. Scope and Methodology
7.2. Brand Positioning Matrix: Antares Pharma
7.3. Brand Positioning Matrix: BD
7.4. Brand Positioning Matrix: Elcam Drug Delivery Devices
7.5. Brand Positioning Matrix: Oval Medical Technologies
7.6. Brand Positioning Matrix: SHL Medical
7.7. Brand Positioning Matrix: Ypsomed
7.8. Brand Positioning Matrix: DALI Medical Devices

8. PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Autoinjectors: Patent Analysis
8.3.1. Analysis by Publication Year
8.3.2. Analysis by Issuing Authority
8.3.3. Analysis by CPC Symbols

8.4. Emerging Focus Areas
8.5. Leading Players: Analysis by Number of Patents
8.6. Autoinjectors: Patent Benchmarking Analysis
8.6.1. Analysis by Patent Characteristics
8.6.2. Analysis by Geography

8.7. Autoinjectors: Patent Valuation Analysis

9. THERAPEUTIC PRODUCTS AVAILABLE IN AUTOINJECTORS
9.1. Chapter Overview
9.2. Autoinjector Combination Products: List of Approved Drugs
9.2.1. Analysis by Initial Year of Approval
9.2.2. Analysis by Usability
9.2.3. Analysis by Route of Administration
9.2.4. Analysis by Type of Molecule
9.2.5. Analysis by Dose Strength
9.2.6. Analysis by Therapeutic Area
9.2.7. Analysis by Other Approved Dosage Forms

9.3. Autoinjector Combination Products: List of Pipeline Drugs
9.3.1. Analysis by Phase of Development
9.3.2. Analysis by Route of Administration
9.3.3. Analysis by Type of Molecule
9.3.4. Analysis by Therapeutic Area

9.4. Autoinjector Combination Products: List of Developers
9.4.1. Analysis by Year of Establishment
9.4.2. Analysis by Company Size
9.4.3. Analysis by Location of Headquarters

10. CASE STUDY: AUTOINJECTOR-BASED COMBINATION PRODUCTS AND AFFILIATED THERAPEUTIC AREAS
10.1. Chapter Overview
10.2. Autoinjector-based Combination Products Available / Under Evaluation
10.3. Anaphylaxis
10.3.1. Overview and Epidemiology
10.3.2. Available Treatment Options: Adrenaline
10.3.2.1. Mechanism of Action
10.3.2.2. History of Development
10.3.3.3. Marketed Autoinjectors
10.3.3.3.1. Adrenaclick®
10.3.3.3.2. Allerject / Auvi-Q® (Formerly called e-cue™)
10.3.3.3.3. Anapen®
10.3.3.3.4. Emerade®
10.3.3.3.5. EpiPen® / EpiPen® Jr
10.3.3.3.6. Jext®
10.3.3.3.7. EpiPen® / EpiPen Jr®

10.3.3.4. Pipeline Autoinjectors
10.3.3.4.1. EpiQ
10.3.3.4.2. ANDIPen
10.3.3.4.3. MiniEpi
10.3.3.4.4. Zeneo® Adrenaline

10.3.3.5. Other Dosage Forms
10.3.3.6. Historical Sales of Approved Products

10.4. Multiple Sclerosis
10.4.1. Overview and Epidemiology
10.4.2. Available Treatment Options: Interferon β-1a and Interferon β-1b
10.4.2.1. Mechanism of Action
10.4.2.2. History of Development
10.4.2.3. Interferon β-1a Autoinjectors
10.4.2.3.1. Avonex® Pen
10.4.2.3.2. PLEGRIDY® Pen
10.4.2.3.3. Rebif® Rebidose®
10.4.2.3.4. RebiSmart™
10.4.2.3.5. Rebiject II®
10.4.2.3.6. ReciGen® Physioject™

10.4.2.4. Interferon β-1b Autoinjectors
10.4.2.4.1. BETACONNECT™
10.4.2.4.2. BETAJECT® Comfort / Betacomfort®
10.4.2.4.3. Betaject® Lite
10.4.2.4.4. ExtaviJect® 30G / ExtaviPro® 30G

10.4.2.5. Other Marketed Autoinjectors
10.4.2.5.1. Cinnomer®40 Physioject™
10.4.2.5.2. CSYNC™ Autoinjector
10.4.2.5.3. WhisperJECT™
10.4.2.5.4. Remurel® Autoxon

10.4.2.6. Other Dosage Forms
10.4.2.7. Historical Sales of Approved Products
10.4.2.7.1. Interferon β-1a
10.4.2.7.2. Interferon β-1b

10.5. Migraine
10.5.1. Overview and Epidemiology
10.5.2. Available Treatment Options: Sumatriptan Succinate
10.5.2.1 History of Development
10.5.2.2 Marketed Autoinjectors
10.5.2.2.1. ALSUMA®
10.5.2.2.2. IMITREX STATdose Pen®
10.5.2.2.3. Zembrace SymTouch
10.5.2.2.4. Aimovig SureClick® Autoinjector
10.5.2.2.5. Emgality® Prefilled Pen

10.5.5. Other Dosage Forms
10.5.6. Historical Sales of Approved Products

10.6. Rheumatoid Arthritis
10.6.1. Overview and Epidemiology
10.6.2. Available Treatment Options
10.6.2.1 History of Development
10.6.2.2. Marketed Autoinjectors for Rheumatoid Arthritis
10.6.2.2.1. Actemra®
10.6.2.2.2. CIMZIA® AutoClicks® Prefilled Pen
10.6.2.2.3. Enbrel SureClick®
10.6.2.2.4. Hulio Prefilled Pen
10.6.2.2.5. HUMIRA® Pen
10.6.2.2.6. ORENCIA® ClickJect™
10.6.2.2.7. OTREXUP™
10.6.2.2.8. Rasuvo® Autoinjector
10.6.2.2.9. SIMPONI® SmartJect® Autoinjector
10.6.2.2.10. KEVZARA® Prefilled Pen
10.6.2.2.11. IMRALDI™ Prefilled Pen

10.6.4. Historical Sales of Approved Products

11. LIKELY DRUG CANDIDATES FOR DELIVERY VIA AUTOINJECTORS
11.1. Chapter Overview
11.2. Marketed Drug Candidates for Delivery via Autoinjectors
11.2.1. Most Likely Drug Candidates
11.2.2. Likely Drug Candidates
11.2.3. Less Likely Drug Candidates
11.2.4. Unlikely Drug Candidates
11.3. Clinical Drug Candidates for Delivery via Autoinjectors
11.3.1. Most Likely Drug Candidates
11.3.2. Likely Drug Candidates
11.3.3. Less Likely Drug Candidates
11.3.4. Unlikely Drug Candidates

12. KEY PLAYERS
12.1. Chapter Overview
12.2. Antares Pharma
12.2.1. Company Overview
12.2.2. Financial Information
12.2.3. Product Portfolio
12.2.3.1. Autoinjectors: Product Details
12.2.3.1.1. Vibex®
12.2.3.1.2. QuickShot™
12.2.3.1.3. BigShot™

12.2.4. Key Collaborators
12.2.4.1. Teva Pharmaceutical
12.2.4.2. Ferring Pharmaceuticals
12.2.4.3. AMAG Pharmaceuticals
12.2.4.4. JCR Pharmaceuticals
12.2.4.5. Pfizer
12.2.4.6. Idorsia Pharmaceuticals

12.2.5. Recent Developments and Future Outlook

12.3 Consort Medical (Previously Bespak)
12.3.1. Company Overview
12.3.2. Financial Information
12.3.3. Technology Overview
12.3.4. Product Portfolio
12.3.4.1. Autoinjectors: Product Details
12.3.4.1.1. Syrina®
12.3.4.1.2. OTS™ Autoinjector
12.3.4.1.3. Viscala Autoinjector

12.3.5. Key Collaborators
12.3.5.1. Aesica Pharmaceuticals
12.3.5.2. Undisclosed Global Biopharmaceutical Company
12.3.5.3. Regeneron Pharmaceuticals

12.3.6. Recent Developments and Future Outlook

12.4. DALI Medical Devices
12.4.1. Company Overview
12.4.2. Product Portfolio
12.4.2.1. Autoinjectors: Product Details
12.4.2.1.1. SAN-L™
12.4.2.1.2. SAN-P
12.4.2.1.3. SAN-DV
12.4.2.1.4. SAN-DV Pro

12.4.3. Collaborations
12.4.3.1. Elcam Medical

12.4.4. Recent Developments and Future Outlook

12.5. Elcam Medical (E3D Elcam Drug Delivery Devices)
12.5.1. Company Overview
12.5.2. Product Portfolio
12.5.2.1. Autoinjectors: Product Details
12.5.2.1.1. Flexi-Q Disposable Autoinjectors
12.5.2.1.1.1. Flexi-Q PFS
12.5.2.1.1.2. Flexi-Q HV
12.5.2.1.1.3. Flexi -Q DV
12.5.2.1.2. Flexi-Q Reusable Autoinjectors
12.5.2.1.2.1. Flexi-Q mMU
12.5.2.1.2.2. Flexi-Q eMU-C / P
12.5.2.1.2.3. Flexi-Q EAI
12.5.3. Comparison of Elcam Medical Autoinjectors
12.5.4. Key Collaborators
12.5.4.1. DALI Medical Devices

12.5.5. Recent Developments and Future Outlook

12.6. Jiangsu Delfu Medical Devices
12.6.1. Company Overview
12.6.2. Financial Information
12.6.3. Product Portfolio
12.6.3.1. Autoinjectors: Overview and Specifications
12.6.3.1.1. Components of Delfu Autoinjectors
12.6.3.1.2. Applications of Delfu Autoinjectors
12.6.3.1.3. Features of Delfu Autoinjectors
12.6.3.1.4. Advantages of Delfu Autoinjectors
12.6.3.1.5. Specifications of Delfu Autoinjectors

12.6.3.2. Autoinjectors: Product Details
12.6.3.2.1. YZ-II 3mL Cartridge Digital Dose Setting GF Autoinjector
12.6.3.2.2. DZ-IA 3 mL Cartridge Needle Hidden Vaccination Autoinjector
12.6.3.2.3. DZ-IA Auto Injector Pen
12.6.3.2.4. Intravitreal Anti-VEGF Injections Electric Insulin Pens
12.6.3.2.5. YZ-III Standard 3 mL Cartridge Reusable Electronic Auto Injector Pen
12.6.3.2.6. YZ-III 0.001mL Dose Increments Fully Automated Reusable Injectors
12.6.3.2.7. YZ-III 0.001 mL Dose Accuracy Auto Injector Pen
12.6.3.2.8. YZ-II 3mL* 1u Auto Injector Pen
12.6.3.2.9. YZ-V 3 mL Cartridge Replaceable Variable-dose Classic Auto Injector Pen
12.6.3.2.10. YZ-III Automatic Reusable Insulin Injection Pen

12.6.4. Recent Developments and Future Outlook

12.7. Oval Medical Technologies
12.7.1. Company Overview
12.7.2. Product Portfolio
12.7.2.1. Autoinjectors: Product Details
12.7.2.1.1 ArQ®
12.7.2.1.2 ArQ® - Bios
12.7.2.1.3 ArQ® - Tempo
12.7.2.1.4 ArQ® - Vita

12.7.3. Key Collaborators
12.7.3.1. SOLIZE

12.7.4. Recent Developments and Future Outlook

12.8. Owen Mumford
12.8.1. Company Overview
12.8.2. Product Portfolio
12.8.2.1. Autoinjectors: Product Details
12.8.2.1.1. Autoject® Micro
12.8.2.1.2. Autoject® 2
12.8.2.1.3. Autoject® Mini
12.8.2.1.4. Autoject® Visco
12.8.2.1.5. UniSafe® Autoinjector
12.8.2.1.6. UniSafe® Connected Auto-injector

12.8.3. Key Collaborators
12.8.3.1. Sanofi Aventis

12.8.4. Recent Developments and Future Outlook

12.9. SHL Group
12.9.1. Company Overview
12.9.2. Product Portfolio
12.9.2.1. Two-Step Disposable Autoinjectors: Product Details
12.9.2.1.1 Amber® (Pushclick™ Technology)
12.9.2.1.2. Molly®
12.9.2.1.3. Molly®RNS
12.9.2.1.4. Molly® 2.25
12.9.2.1.5. Rotaject®
12.9.2.1.6. Bertha®
12.9.2.1.7. DAI® 2
12.9.2.1.8. Maggie®
12.9.2.1.9. Comparison of SHL Two-Step Autoinjectors

12.9.2.2. Three-Step Disposable Autoinjectors: Product Details
12.9.2.2.1. DAI®
12.9.2.2.2. SDI-MIX®+NIT™ (Needle Isolation Technology and Twist and Mix Mechanism)
12.9.2.2.3. VSDI®+NIT®
12.9.2.2.4. Comparison of SHL Three-Step Autoinjectors
12.9.2.2.5. PPI® Injector (Rotaject™ Pressure Release Technology)

12.9.3. Key Collaborators
12.9.3.1. Schreiner MediPharm
12.9.3.2. QuiO

12.9.4. Recent Developments and Future Outlook

12.10. Union Medico®
12.10.1. Company Overview
12.10.2. Technology Overview
12.10.3. Product Portfolio
12.10.3.1. Autoinjectors: Product Details
12.10.3.1.1 45˚ Autoinjector
12.10.3.1.2 45˚/ S Autoinjector
12.10.3.1.3 45˚/ M Autoinjector
12.10.3.1.4 45˚/ R Autoinjector
12.10.3.1.5 Comparison of 45˚ Autoinjectors
12.10.3.1.6 90˚Autoinjector
12.10.3.1.7 90˚/ S Autoinjector
12.10.3.1.8 90˚/ M Autoinjector
12.10.3.1.9 90˚/ XL Autoinjector
12.10.3.1.10 SuperGrip™ Autoinjector
12.10.3.1.11 Exclusive™ Autoinjector
12.10.3.1.12 Comparison of 90˚ Autoinjectors

12.10.4. Recent Developments and Future Outlook

12.11. Ypsomed
12.11.1. Company Overview
12.11.2. Financial Information
12.11.3. Product Portfolio
12.11.3.1. Autoinjectors: Product details
12.11.3.1.1. YpsoMate® ,YpsoMate® 2.25 and YpsoMate® 2.25Pro
12.11.3.1.2. VarioJect™
12.11.3.1.3. Comparison of Autoinjectors

12.11.4. Key Collaborators
12.11.4.1. I-SENS
12.11.4.2. Royal Philips
12.11.4.3. JDRF

12.11.5. Recent Developments and Future Outlook

13. EMERGING PLAYERS
13.1. Chapter Overview
13.2. AktiVax
13.3. Amneal Pharmaceuticals
13.4. kaléo
13.5. MiniEpi
13.6. Nemera
13.7. Nuance Designs
13.8. Windgap Medical
13.9. Xeris Pharmaceuticals
13.10. Zion Clinical Pharmacy

14. KOL ANALYSIS
14.1. Chapter Overview
14.2. Methodology
14.3. KOL Analysis: Principal Investigators / Sub-Investigators / Study Directors Involved in Clinical Trials
14.3.1. Geographical Distribution of KOLs

14.3. KOL Analysis: Patent Assignees
14.3.1. Geographical Distribution of KOLs

15. SWOT ANALYSIS
15.1. Chapter Overview
15.2. Strengths
15.3. Weaknesses
15.4. Opportunities
15.5. Threats
15.6. Concluding Remarks

16. CASE STUDY: MEDICAL DEVICE CONTRACT SERVICE PROVIDERS
16.1. Chapter Overview
16.2. Challenges Associated with Medical Device Manufacturing
16.3. Role of CMOs in Medical Device Manufacturing
16.4. Services Offered by Medical Device CMOs
16.5. Advantages Offered by Medical Device CMOs
16.6. Risks Associated with Outsourcing to CMOs
16.7. Drug Delivery Service Providers
16.8. Concluding Remarks

17. MARKET SIZING AND OPPORTUNITY ANALYSIS
17.1. Chapter Overview
17.2. Forecast Methodology and Key Assumptions
17.3. Global Autoinjectors Market, 2020-2030 (By Value)
17.3.1. Global Autoinjectors Market: Distribution by Usability, 2020-2030 (By Value)
17.3.2. Global Autoinjectors Market: Distribution by Route of Administration, 2020-2030 (By Value)
17.3.3. Global Autoinjectors Market: Distribution by Type of Molecule, 2020-2030 (By Value)

17.3.4. Autoinjectors Market in North America, 2020-2030 (By Value)
17.3.4.1. Autoinjectors Market in North America: Distribution by Usability, 2020-2030 (By Value)
17.3.4.2. Autoinjectors Market in North America: Distribution by Route of Administration, 2020-2030 (By Value)
17.3.4.3. Autoinjectors Market in North America: Distribution by Type of Molecule, 2020-2030 (By Value)

17.3.5. Autoinjectors Market in Europe, 2020-2030 (By Value)
17.3.5.1. Autoinjectors Market in Europe: Distribution by Usability, 2020-2030 (By Value)
17.3.5.2. Autoinjectors Market in Europe: Distribution by Route of Administration, 2020-2030 (By Value)
17.3.5.3. Autoinjectors Market in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)

17.3.6. Autoinjectors Market in Asia Pacific, 2020-2030 (By Value)
17.3.6.1. Autoinjectors Market in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)
17.3.6.2. Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)
17.3.6.3. Autoinjectors Market in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)

17.3.7. Autoinjectors Market in Rest of the World, 2020-2030 (By Value)
17.3.7.1. Autoinjectors Market in Rest of the World: Distribution by Usability, 2020-2030 (By Value)
17.3.7.2. Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)
17.3.7.3. Autoinjectors Market in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)

17.4. Global Autoinjectors Market, 2020-2030 (By Volume)
17.4.1. Global Autoinjectors Market: Distribution by Usability, 2020-2030 (By Volume)
17.4.2. Global Autoinjectors Market: Distribution by Route of Administration, 2020-2030 (By Volume)
17.4.3. Global Autoinjectors Market: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.4.4. Autoinjectors Market in North America, 2020-2030 (By Volume)
17.3.4.1. Autoinjectors Market in North America: Distribution by Usability, 2020-2030 (By Volume)
17.3.4.2. Autoinjectors Market in North America: Distribution by Route of Administration, 2020-2030 (By Volume)
17.3.4.3. Autoinjectors Market in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.3.5. Autoinjectors Market in Europe, 2020-2030 (By Volume)
17.3.5.1. Autoinjectors Market in Europe: Distribution by Usability, 2020-2030 (By Volume)
17.3.5.2. Autoinjectors Market in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)
17.3.5.3. Autoinjectors Market in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.3.6. Autoinjectors Market in Asia Pacific, 2020-2030 (By Volume)
17.3.6.1. Autoinjectors Market in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)
17.3.6.2. Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)
17.3.6.3. Autoinjectors Market in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.3.7. Autoinjectors Market in Rest of the World, 2020-2030 (By Volume)
17.3.7.1. Autoinjectors Market in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)
17.3.7.2. Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)
17.3.7.3. Autoinjectors Market in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.5. Global Autoinjectors Market for Anaphylaxis, 2020-2030 (By Value)
17.5.1. Autoinjectors Market for Anaphylaxis in North America, 2020-2030 (By Value)
17.5.1.1. Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2020-2030 (By Value)
17.5.1.2. Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2020-2030 (By Value)
17.5.1.3. Autoinjectors Market for Anaphylaxis in North America: Distribution by Type of Molecule, 2020-2030 (By Value)

17.5.2. Autoinjectors Market for Anaphylaxis in Europe, 2020-2030 (By Value)
17.5.2.1. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2020-2030 (By Value)
17.5.2.2. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2020-2030 (By Value)
17.5.2.3. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)

17.5.3. Autoinjectors Market for Anaphylaxis in Asia Pacific, 2020-2030 (By Value)
17.5.3.1. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)
17.5.3.2. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)
17.5.3.3. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)

17.5.4. Autoinjectors Market for Anaphylaxis in Rest of the World, 2020-2030 (By Value)
17.5.4.1. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2020-2030 (By Value)
17.5.4.2. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)
17.5.4.3. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)

17.6. Global Autoinjectors Market for Anaphylaxis, 2020-2030 (By Volume)
17.6.1. Autoinjectors Market for Anaphylaxis in North America, 2020-2030 (By Volume)
17.6.1.1. Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2020-2030 (By Volume)
17.6.1.2. Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2020-2030 (By Volume)
17.6.1.3. Autoinjectors Market for Anaphylaxis in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.6.2. Autoinjectors Market for Anaphylaxis in Europe, 2020-2030 (By Volume)
17.6.2.1. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2020-2030 (By Volume)
17.6.2.2. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)
17.6.2.3. Autoinjectors Market for Anaphylaxis in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.6.3. Autoinjectors Market for Anaphylaxis in Asia Pacific, 2020-2030 (By Volume)
17.6.3.1. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)
17.6.3.2. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)
17.6.3.3. Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.6.4. Autoinjectors Market for Anaphylaxis in Rest of the World, 2020-2030 (By Volume)
17.6.4.1. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)
17.6.4.2. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)
17.6.4.3. Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.7. Global Autoinjectors Market for Multiple Sclerosis, 2020-2030 (By Value)
17.7.1. Autoinjectors Market for Multiple Sclerosis in North America, 2020-2030 (By Value)
17.7.1.1. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2020-2030 (By Value)
17.7.1.2. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2020-2030 (By Value)
17.7.1.3. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Type of Molecule, 2020-2030 (By Value)

17.7.2. Autoinjectors Market for Multiple Sclerosis in Europe, 2020-2030 (By Value)
17.7.2.1. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2020-2030 (By Value)
17.7.2.2. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2020-2030 (By Value)
17.7.2.3. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)

17.7.3. Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2020-2030 (By Value)
17.7.3.1. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)
17.7.3.2. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)
17.7.3.3. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)

17.7.4. Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2020-2030 (By Value)
17.7.4.1. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2020-2030 (By Value)
17.7.4.2. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)
17.7.4.3. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)

17.8. Global Autoinjectors Market for Multiple Sclerosis, 2020-2030 (By Volume)
17.8.1. Autoinjectors Market for Multiple Sclerosis in North America, 2020-2030 (By Volume)
17.8.1.1. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2020-2030 (By Volume)
17.8.1.2. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2020-2030 (By Volume)
17.8.1.3. Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.8.2. Autoinjectors Market for Multiple Sclerosis in Europe, 2020-2030 (By Volume)
17.8.2.1. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2020-2030 (By Volume)
17.8.2.2. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)
17.8.2.3. Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.8.3. Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2020-2030 (By Volume)
17.8.3.1. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)
17.8.3.2. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)
17.8.3.3. Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.8.4. Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2020-2030 (By Volume)
17.8.4.1. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)
17.8.4.2. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)
17.8.4.3. Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.9. Global Autoinjectors Market for Rheumatoid Arthritis, 2020-2030 (By Value)
17.9.1. Autoinjectors Market for Rheumatoid Arthritis in North America, 2020-2030 (By Value)
17.9.1.1. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2020-2030 (By Value)
17.9.1.2. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2020-2030 (By Value)
17.9.1.3. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Type of Molecule, 2020-2030 (By Value)

17.9.2. Autoinjectors Market for Rheumatoid Arthritis in Europe, 2020-2030 (By Value)
17.9.2.1. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2020-2030 (By Value)
17.9.2.2. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2020-2030 (By Value)
17.9.2.3. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)

17.9.3. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2020-2030 (By Value)
17.9.3.1. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)
17.9.3.2. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)
17.9.3.3. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)

17.9.4. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2020-2030 (By Value)
17.9.4.1. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2020-2030 (By Value)
17.9.4.2. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)
17.9.4.3. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)

17.10. Global Autoinjectors Market for Rheumatoid Arthritis, 2020-2030 (By Volume)
17.10.1. Autoinjectors Market for Rheumatoid Arthritis in North America, 2020-2030 (By Volume)
17.10.1.1. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2020-2030 (By Volume)
17.10.1.2. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2020-2030 (By Volume)
17.10.1.3. Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.10.2. Autoinjectors Market for Rheumatoid Arthritis in Europe, 2020-2030 (By Volume)
17.10.2.1. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2020-2030 (By Volume)
17.10.2.2. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)
17.10.2.3. Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.10.3. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2020-2030 (By Volume)
17.10.3.1. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)
17.10.3.2. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)
17.10.3.3. Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.10.4. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2020-2030 (By Volume)
17.10.4.1. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)
17.10.4.2. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)
17.10.4.3. Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.11. Global Autoinjectors Market for Migraine, 2020-2030 (By Value)
17.11.1. Autoinjectors Market for Migraine in North America, 2020-2030 (By Value)
17.11.1.1. Autoinjectors Market for Migraine in North America: Distribution by Usability, 2020-2030 (By Value)
17.11.1.2. Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2020-2030 (By Value)
17.11.1.3. Autoinjectors Market for Migraine in North America: Distribution by Type of Molecule, 2020-2030 (By Value)

17.11.2. Autoinjectors Market for Migraine in Europe, 2020-2030 (By Value)
17.11.2.1. Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2020-2030 (By Value)
17.11.2.2. Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2020-2030 (By Value)
17.11.2.3. Autoinjectors Market for Migraine in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)

17.11.3. Autoinjectors Market for Migraine in Asia Pacific, 2020-2030 (By Value)
17.11.3.1. Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)
17.11.3.2. Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)
17.11.3.3. Autoinjectors Market for Migraine in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)

17.11.4. Autoinjectors Market for Migraine in Rest of the World, 2020-2030 (By Value)
17.11.4.1. Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2020-2030 (By Value)
17.11.4.2. Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)
17.11.4.3. Autoinjectors Market for Migraine in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)

17.12. Global Autoinjectors Market for Migraine, 2020-2030 (By Volume)
17.12.1. Autoinjectors Market for Migraine in North America, 2020-2030 (By Volume)
17.12.1.1. Autoinjectors Market for Migraine in North America: Distribution by Usability, 2020-2030 (By Volume)
17.12.1.2. Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2020-2030 (By Volume)
17.12.1.3. Autoinjectors Market for Migraine in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.12.2. Autoinjectors Market for Migraine in Europe, 2020-2030 (By Volume)
17.12.2.1. Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2020-2030 (By Volume)
17.12.2.2. Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)
17.12.2.3. Autoinjectors Market for Migraine in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.12.3. Autoinjectors Market for Migraine in Asia Pacific, 2020-2030 (By Volume)
17.12.3.1. Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)
17.12.3.2. Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)
17.12.3.3. Autoinjectors Market for Migraine in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.12.4. Autoinjectors Market for Migraine in Rest of the World, 2020-2030 (By Volume)
17.12.4.1. Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)
17.12.4.2. Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)
17.12.4.3. Autoinjectors Market for Migraine in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.13. Global Autoinjectors Market for Diabetes, 2020-2030 (By Value)
17.13.1. Autoinjectors Market for Diabetes in North America, 2020-2030 (By Value)
17.13.1.1. Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2020-2030 (By Value)
17.13.1.2. Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2020-2030 (By Value)
17.13.1.3. Autoinjectors Market for Diabetes in North America: Distribution by Type of Molecule, 2020-2030 (By Value)

17.13.2. Autoinjectors Market for Diabetes in Europe, 2020-2030 (By Value)
17.13.2.1. Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2020-2030 (By Value)
17.13.2.2. Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2020-2030 (By Value)
17.13.2.3. Autoinjectors Market for Diabetes in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)

17.13.3. Autoinjectors Market for Diabetes in Asia Pacific, 2020-2030 (By Value)
17.13.3.1. Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)
17.13.3.2. Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)
17.13.3.3. Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)

17.13.4. Autoinjectors Market for Diabetes in Rest of the World, 2020-2030 (By Value)
17.13.4.1. Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2020-2030 (By Value)
17.13.4.2. Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)
17.13.4.3. Autoinjectors Market for Diabetes in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)

17.14. Global Autoinjectors Market for Diabetes, 2020-2030 (By Volume)
17.14.1. Autoinjectors Market for Diabetes in North America, 2020-2030 (By Volume)
17.14.1.1. Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2020-2030 (By Volume)
17.14.1.2. Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2020-2030 (By Volume)
17.14.1.3. Autoinjectors Market for Diabetes in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.14.2. Autoinjectors Market for Diabetes in Europe, 2020-2030 (By Volume)
17.14.2.1. Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2020-2030 (By Volume)
17.14.2.2. Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)
17.14.2.3. Autoinjectors Market for Diabetes in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.14.3. Autoinjectors Market for Diabetes in Asia Pacific, 2020-2030 (By Volume)
17.14.3.1. Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)
17.14.3.2. Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)
17.14.3.3. Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.14.4. Autoinjectors Market for Diabetes in Rest of the World, 2020-2030 (By Volume)
17.14.4.1. Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)
17.14.4.2. Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)
17.14.4.3. Autoinjectors Market for Diabetes in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.15. Global Autoinjectors Market for Other Indications, 2020-2030 (By Value)
17.15.2. Autoinjectors Market for Other Indications in North America, 2020-2030 (By Value)
17.15.2.1. Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2020-2030 (By Value)
17.15.2.2. Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2020-2030 (By Value)
17.15.2.3. Autoinjectors Market for Other Indications in North America: Distribution by Type of Molecule, 2020-2030 (By Value)

17.15.3. Autoinjectors Market for Other Indications in Europe, 2020-2030 (By Value)
17.15.3.1. Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2020-2030 (By Value)
17.15.3.2. Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2020-2030 (By Value)
17.15.3.3. Autoinjectors Market for Other Indications in Europe: Distribution by Type of Molecule, 2020-2030 (By Value)

17.15.4. Autoinjectors Market for Other Indications in Asia Pacific, 2020-2030 (By Value)
17.15.4.1. Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)
17.15.4.2. Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Value)
17.15.4.3. Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Value)

17.15.5. Autoinjectors Market for Other Indications in Rest of the World, 2020-2030 (By Value)
17.15.5.1. Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2020-2030 (By Value)
17.15.5.2. Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Value)
17.15.5.3. Autoinjectors Market for Other Indications in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Value)

17.16. Global Autoinjectors Market for Other Indications, 2020-2030 (By Volume)
17.16.1. Autoinjectors Market for Other Indications in North America, 2020-2030 (By Volume)
17.16.1.1. Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2020-2030 (By Volume)
17.16.1.2. Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2020-2030 (By Volume)
17.16.1.3. Autoinjectors Market for Other Indications in North America: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.16.2. Autoinjectors Market for Other Indications in Europe, 2020-2030 (By Volume)
17.16.2.1. Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2020-2030 (By Volume)
17.16.2.2. Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2020-2030 (By Volume)
17.16.2.3. Autoinjectors Market for Other Indications in Europe: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.16.3. Autoinjectors Market for Other Indications in Asia Pacific, 2020-2030 (By Volume)
17.16.3.1. Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2020-2030 (By Volume)
17.16.3.2. Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2020-2030 (By Volume)
17.16.3.3. Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (By Volume)

17.16.4. Autoinjectors Market for Other Indications in Rest of the World, 2020-2030 (By Volume)
17.16.4.1. Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2020-2030 (By Volume)
17.16.4.2. Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2020-2030 (By Volume)
17.16.4.3. Autoinjectors Market for Other Indications in Rest of the World: Distribution by Type of Molecule, 2020-2030 (By Volume)

18. CONCLUSION
18.1. Chapter Overview
18.2. Key Takeaways

19. INTERVIEW TRANSCRIPTS
19.1. Chapter Overview
19.2. DALI Medical Devices
19.2.1. Company Snapshot
19.2.2. Interview Transcript: David Daily, CEO and Co-Founder

19.3. PHC
19.3.1. Company Snapshot
19.3.2. Interview Transcript: Douglas Marenzi, Managing Director

19.4. Elcam Medical
19.4.1. Company Snapshot
19.4.2. Interview Transcript: Tsachi Shaked, Senior Marketing and BD Director, Injectable Drug Delivery Devices

20. APPENDIX 1: TABULATED DATA

21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figuers

Figure 3.1 Popular Drug Delivery Systems
Figure 3.2 Types of Self-Injection Devices
Figure 3.3 Components of an Autoinjector
Figure 3.4 Cartridge Based Autoinjectors versus Prefilled Syringe Based Autoinjectors
Figure 3.5 Classification of Autoinjectors
Figure 5.1 Autoinjectors: Distribution by Usability
Figure 5.2 Autoinjectors: Distribution by Type of Primary Container
Figure 5.3 Autoinjectors: Distribution by Volume of Container
Figure 5.4 Autoinjectors: Distribution by Type of Dose
Figure 5.5 Autoinjectors: Distribution by Route of Administration
Figure 5.6 Autoinjectors: Distribution by Actuation Mechanism
Figure 5.7 Autoinjectors: Distribution by Type of Feedback Mechanism
Figure 5.8 Autoinjector Device Developers: Distribution by Year of Establishment
Figure 5.9 Autoinjector Device Developers: Distribution by Company Size
Figure 5.10 Autoinjector Device Developers: Distribution by Geographical Location of Headquarters
Figure 5.11 Autoinjector Device Developers: Distribution by Geographical Location of Manufacturing Facilities
Figure 6.1 Product Competitiveness Analysis: Disposable Autoinjectors
Figure 6.2 Product Competitiveness Analysis: Reusable Autoinjectors
Figure 7.1 Brand Positioning Matrix: Antares Pharma
Figure 7.2 Brand Positioning Matrix: BD
Figure 7.3 Brand Positioning Matrix: Elcam Drug Delivery Devices
Figure 7.4 Brand Positioning Matrix: Oval Medical Technologies
Figure 7.5 Brand Positioning Matrix: SHL Medical
Figure 7.6 Brand Positioning Matrix: Ypsomed
Figure 7.7 Brand Positioning Matrix: DALI Medical Devices
Figure 8.1 Patent Portfolio: Distribution by Type of Patent
Figure 8.2 Patent Portfolio: Cumulative Distribution by Publication Year
Figure 8.3 Patent Portfolio: Year-wise Distribution by Publication Year
Figure 8.4 Patent Portfolio: Distribution by Issuing Authority
Figure 8.5 Patent Portfolio: Distribution by CPC Symbols
Figure 8.6 Patent Portfolio: Emerging Focus Areas
Figure 8.7 Leading Players: Distribution by Number of Patents
Figure 8.8 Patent Portfolio: Benchmarking by Patent Characteristics
Figure 8.9 Patent Portfolio: Benchmarking International Patents
Figure 8.10 Patent Portfolio: Distribution of Patents by Geography and Type
Figure 8.11 Patent Portfolio: Distribution by Patent Age
Figure 8.12 Patent Portfolio: Valuation Analysis
Figure 9.1 Approved Autoinjector Combination Products: Distribution by Initial Year of Approval
Figure 9.2 Approved Autoinjector Combination Products: Distribution by Usability
Figure 9.3 Approved Autoinjector Combination Products: Distribution by Route of Administration
Figure 9.4 Approved Autoinjector Combination Products: Distribution by Type of Molecule
Figure 9.5 Approved Autoinjector Combination Products: Distribution by Dose Strength
Figure 9.6 Approved Autoinjector Combination Products: Distribution by Therapeutic Area
Figure 9.7 Approved Autoinjector Combination Products: Distribution by Other Approved Dosage Forms
Figure 9.8 Pipeline Autoinjector Combination Products: Distribution by Phase of Development
Figure 9.9 Pipeline Autoinjector Combination Products: Distribution by Route of Administration
Figure 9.10 Pipeline Autoinjector Combination Products: Distribution by Type of Molecule
Figure 9.11 Pipeline Autoinjector Combination Products: Distribution by Therapeutic Area
Figure 9.12 Autoinjector Combination Product Developers: Distribution by Year of Establishment
Figure 9.13 Autoinjector Combination Product Developers: Distribution by Company Size
Figure 9.14 Autoinjector Combination Product Developers: Distribution by Geographical Location of Headquarters
Figure 10.1 Anaphylaxis: History of Drug Development
Figure 10.2 EpiPen®: Historical Drug Sales (USD Billion), 2012-2017
Figure 10.3 Multiple Sclerosis: History of Drug Development
Figure 10.4 Interferon β-1a: Historical Sales (USD Billion), 2014-H1 2019
Figure 10.5 Interferon β-1b: Historical Sales (USD Million), 2014-H1 2019
Figure 10.6 Migraine: History of Drug Development
Figure 10.7 Migraine: Historical Drug Sales (USD Million), 2014-H1 2019
Figure 10.8 Rheumatoid Arthritis: History of Drug Development
Figure 10.9 Rheumatoid Arthritis: Historical Drug Sales (USD Billion), 2014-H1 2019
Figure 11.1 Likely Drug Candidates: Marketed Drugs
Figure 11.2 Likely Drug Candidates: Pipeline Drugs
Figure 12.1 Antares Pharma: Annual Revenues, 2014-H1 2019 (USD Million)
Figure 12.2 Antares Pharma: Product Portfolio
Figure 12.3 Consort Medical: Annual Revenues, FY 13/14-FY 18/19 (GBP Million)
Figure 12.4 Consort Medical Injectables: Syrina Autoinjectors
Figure 12.5 DALI Medical Devices: Autoinjectors
Figure 12.6 SAN-L: Mechanism of Drug Delivery
Figure 12.7 SAN-P: Mechanism of Drug Delivery
Figure 12.8 SAN-DV: Mechanism of Drug Delivery
Figure 12.9 SAN-DV Pro: Mechanism of Drug Delivery
Figure 12.10 Elcam Medical: Product Portfolio
Figure 12.11 Elcam Medical: Flexi-Q Autoinjectors
Figure 12.12 Flexi-Q PFS: Components
Figure 12.13 Flexi-Q PFS: Mechanism of Drug Delivery
Figure 12.14 Flexi-Q DV: Components
Figure 12.15 Flexi-Q DV: Mechanism of Drug Delivery
Figure 12.16 Flexi-Q mMU: Components
Figure 12.17 Flexi-Q eMU: Components
Figure 12.18 Flexi-Q mMU / Flexi-Q eMU: Mechanism of Drug Delivery
Figure 12.19 Flexi-Q EAI: Mechanism of Drug Delivery
Figure 12.20 Delfu Autoinjectors: Components
Figure 12.21 Applications of Delfu Autoinjectors
Figure 12.22 Oval Medical Technologies: Product Portfolio
Figure 12.23 ArQ®: Mechanism of Drug Delivery
Figure 12.24 ArQ®-Bios: Mechanism of Drug Delivery
Figure 12.25 ArQ®-Tempo: Mechanism of Drug Delivery
Figure 12.26 Owen Mumford: Product Portfolio
Figure 12.27 Autoject® Micro: Mechanism of Drug Delivery
Figure 12.28 Autoject® 2 Autoinjector: Mechanism of Drug Delivery
Figure 12.29 Autoject® Mini: Mechanism of Drug Delivery
Figure 12.30 SHL Medical: Product Portfolio
Figure 12.31 SHL Medical: Prefilled Syringe Based Autoinjectors
Figure 12.32 SHL Medical: Cartridge Based Autoinjectors
Figure 12.33 SHL Medical: Two-Step Autoinjectors
Figure 12.34 SHL Medical Two-Step Autoinjectors: Mechanism of Drug Delivery
Figure 12.35 SHL Medical: Three-Step Autoinjectors
Figure 12.36 DAI®: Mechanism of Drug Delivery
Figure 12.37 SDI-MIX®+NIT™: Mechanism of Drug Delivery
Figure 12.38 Union Medico: 45˚Autoinjector Portfolio
Figure 12.39 Union Medico: Parts of 45˚/R Autoinjector
Figure 12.40 Union Medico: Types of 45˚/R Autoinjector
Figure 12.41 Union Medico: Types of 90˚ Autoinjectors
Figure 12.42 Exclusive™: Components
Figure 12.43 Ypsomed: Annual Revenues, FY 14/15-FY 18/19 (CHF Million)
Figure 12.44 Ypsomed: Sales by Business Divisions, FY 18/19 (CHF Million, %)
Figure 12.45 Ypsomed: Product Portfolio
Figure 12.46 YpsoMate®: Mechanism of Drug Delivery
Figure 12.47 VarioJect™: Mechanism of Drug Delivery
Figure 14.1 Geographical Distribution of Principal Investigators
Figure 14.2 KOL Benchmarking: Roots Analysis versus Third Party Scoring
Figure 14.3 Geographical Distribution of Patent Applicants
Figure 15.1 Autoinjectors SWOT Analysis: Overview
Figure 15.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 16.1 Challenges Associated with Medical Device Manufacturing
Figure 16.2 Services Offered by Medical Device CMOs
Figure 16.3 Advantages of Outsourcing to CMOs
Figure 16.4 Risks Associated with Outsourcing to CMOs
Figure 17.1 Global Autoinjectors Market, 2020-2030 (USD Million)
Figure 17.2 Global Autoinjectors Market: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.3 Global Autoinjectors Market: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.4 Autoinjectors Market in North America, 2020-2030 (USD Million)
Figure 17.5 Autoinjectors Market in North America: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.6 Autoinjectors Market in North America: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.7 Autoinjectors Market in North America: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.8 Autoinjectors Market in Europe, 2020-2030 (USD Million)
Figure 17.9 Autoinjectors Market in Europe: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.10 Autoinjectors Market in Europe: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.11 Autoinjectors Market in Europe: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.12 Autoinjectors Market in Asia Pacific, 2020-2030 (USD Million)
Figure 17.13 Autoinjectors Market in Asia Pacific: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.14 Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.15 Autoinjectors Market in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.16 Autoinjectors Market in Rest of the World, 2020-2030 (USD Million)
Figure 17.17 Autoinjectors Market in Rest of the World: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.18 Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.19 Autoinjectors Market in Rest of the World: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.20 Global Autoinjectors Market, 2020-2030 (Units, Million)
Figure 17.21 Global Autoinjectors Market: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.22 Global Autoinjectors Market: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.23 Global Autoinjectors Market: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.24 Autoinjectors Market in North America, 2020-2030 (Units, Million)
Figure 17.25 Autoinjectors Market in North America: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.26 Autoinjectors Market in North America: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.27 Autoinjectors Market in North America: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.28 Autoinjectors Market in Europe, 2020-2030 (Units, Million)
Figure 17.29 Autoinjectors Market in Europe: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.30 Autoinjectors Market in Europe: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.31 Autoinjectors Market in Europe: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.32 Autoinjectors Market in Asia Pacific, 2020-2030 (Units, Million)
Figure 17.33 Autoinjectors Market in Asia Pacific: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.34 Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.35 Autoinjectors Market in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.36 Autoinjectors Market in Rest of the World, 2020-2030 (Units, Million)
Figure 17.37 Autoinjectors Market in Rest of the World: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.38 Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.39 Autoinjectors Market in Rest of the World: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.40 Global Autoinjectors Market for Anaphylaxis, 2020-2030 (USD Million)
Figure 17.41 Autoinjectors Market for Anaphylaxis in North America, 2020-2030 (USD Million)
Figure 17.42 Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.43 Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.44 Autoinjectors Market for Anaphylaxis in North America: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.45 Autoinjectors Market for Anaphylaxis in Europe, 2020-2030 (USD Million)
Figure 17.46 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.47 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.48 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.49 Autoinjectors Market for Anaphylaxis in Asia Pacific, 2020-2030 (USD Million)
Figure 17.50 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.51 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.52 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.53 Autoinjectors Market for Anaphylaxis in Rest of the World, 2020-2030 (USD Million)
Figure 17.54 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.55 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.56 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.57 Global Autoinjectors Market for Anaphylaxis, 2020-2030 (Units, Million)
Figure 17.58 Autoinjectors Market for Anaphylaxis in North America, 2020-2030 (Units, Million)
Figure 17.59 Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.60 Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.61 Autoinjectors Market for Anaphylaxis in North America: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.62 Autoinjectors Market for Anaphylaxis in Europe, 2020-2030 (Units, Million)
Figure 17.63 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.64 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.65 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.66 Autoinjectors Market for Anaphylaxis in Asia Pacific, 2020-2030 (Units, Million)
Figure 17.67 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.68 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.69 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.70 Autoinjectors Market for Anaphylaxis in Rest of the World, 2020-2030 (Units, Million)
Figure 17.71 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.72 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.73 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.74 Global Autoinjectors Market for Multiple Sclerosis, 2020-2030 (USD Million)
Figure 17.75 Autoinjectors Market for Multiple Sclerosis in North America, 2020-2030 (USD Million)
Figure 17.76 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.77 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.78 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.79 Autoinjectors Market for Multiple Sclerosis in Europe, 2020-2030 (USD Million)
Figure 17.80 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.81 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.82 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.83 Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2020-2030 (USD Million)
Figure 17.84 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.85 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.86 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.87 Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2020-2030 (USD Million)
Figure 17.88 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.89 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.90 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.91 Global Autoinjectors Market for Multiple Sclerosis, 2020-2030 (Units, Million)
Figure 17.92 Autoinjectors Market for Multiple Sclerosis in North America, 2020-2030 (Units, Million)
Figure 17.93 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.94 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.95 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.96 Autoinjectors Market for Multiple Sclerosis in Europe, 2020-2030 (Units, Million)
Figure 17.97 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.98 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.99 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.100 Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2020-2030 (Units, Million)
Figure 17.101 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.102 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.103 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.104 Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2020-2030 (Units, Million)
Figure 17.105 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.106 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.107 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.108 Global Autoinjectors Market for Rheumatoid Arthritis, 2020-2030 (USD Million)
Figure 17.109 Autoinjectors Market for Rheumatoid Arthritis in North America, 2020-2030 (USD Million)
Figure 17.110 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.111 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.112 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.113 Autoinjectors Market for Rheumatoid Arthritis in Europe, 2020-2030 (USD Million)
Figure 17.114 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.115 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.116 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.117 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2020-2030 (USD Million)
Figure 17.118 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.119 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.120 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.121 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2020-2030 (USD Million)
Figure 17.122 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.123 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.124 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.125 Global Autoinjectors Market for Rheumatoid Arthritis, 2020-2030 (Units, Million)
Figure 17.126 Autoinjectors Market for Rheumatoid Arthritis in North America, 2020-2030 (Units, Million)
Figure 17.127 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.128 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.129 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.130 Autoinjectors Market for Rheumatoid Arthritis in Europe, 2020-2030 (Units, Million)
Figure 17.131 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.132 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.133 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.134 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2020-2030 (Units, Million)
Figure 17.135 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.136 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.137 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.138 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2020-2030 (Units, Million)
Figure 17.139 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.140 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.141 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.142 Global Autoinjectors Market for Migraine, 2020-2030 (USD Million)
Figure 17.143 Autoinjectors Market for Migraine in North America, 2020-2030 (USD Million)
Figure 17.144 Autoinjectors Market for Migraine in North America: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.145 Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.146 Autoinjectors Market for Migraine in North America: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.147 Autoinjectors Market for Migraine in Europe, 2020-2030 (USD Million)
Figure 17.148 Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.149 Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.150 Autoinjectors Market for Migraine in Europe: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.151 Autoinjectors Market for Migraine in Asia Pacific, 2020-2030 (USD Million)
Figure 17.152 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.153 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.154 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.155 Autoinjectors Market for Migraine in Rest of the World, 2020-2030 (USD Million)
Figure 17.156 Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.157 Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.158 Autoinjectors Market for Migraine in Rest of the World: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.159 Global Autoinjectors Market for Migraine, 2020-2030 (Units, Million)
Figure 17.160 Autoinjectors Market for Migraine in North America, 2020-2030 (Units, Million)
Figure 17.161 Autoinjectors Market for Migraine in North America: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.162 Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.163 Autoinjectors Market for Migraine in North America: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.164 Autoinjectors Market for Migraine in Europe, 2020-2030 (Units, Million)
Figure 17.165 Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.166 Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.167 Autoinjectors Market for Migraine in Europe: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.168 Autoinjectors Market for Migraine in Asia Pacific, 2020-2030 (Units, Million)
Figure 17.169 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.170 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.171 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.172 Autoinjectors Market for Migraine in Rest of the World, 2020-2030 (Units, Million)
Figure 17.173 Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.174 Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.175 Autoinjectors Market for Migraine in Rest of the World: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.176 Global Autoinjectors Market for Diabetes, 2020-2030 (USD Million)
Figure 17.177 Autoinjectors Market for Diabetes in North America, 2020-2030 (USD Million)
Figure 17.178 Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.179 Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.180 Autoinjectors Market for Diabetes in North America: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.181 Autoinjectors Market for Diabetes in Europe, 2020-2030 (USD Million)
Figure 17.182 Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.183 Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.184 Autoinjectors Market for Diabetes in Europe: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.185 Autoinjectors Market for Diabetes in Asia Pacific, 2020-2030 (USD Million)
Figure 17.186 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.187 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.188 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.189 Autoinjectors Market for Diabetes in Rest of the World, 2020-2030 (USD Million)
Figure 17.190 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.191 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.192 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.193 Global Autoinjectors Market for Diabetes, 2020-2030 (Units, Million)
Figure 17.194 Autoinjectors Market for Diabetes in North America, 2020-2030 (Units, Million)
Figure 17.195 Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.196 Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.197 Autoinjectors Market for Diabetes in North America: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.198 Autoinjectors Market for Diabetes in Europe, 2020-2030 (Units, Million)
Figure 17.199 Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.200 Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.201 Autoinjectors Market for Diabetes in Europe: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.202 Autoinjectors Market for Diabetes in Asia Pacific, 2020-2030 (Units, Million)
Figure 17.203 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.204 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.205 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.206 Autoinjectors Market for Diabetes in Rest of the World, 2020-2030 (Units, Million)
Figure 17.207 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.208 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.209 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.210 Global Autoinjectors Market for Other Indications, 2020-2030 (USD Million)
Figure 17.211 Autoinjectors Market for Other Indications in North America, 2020-2030 (USD Million)
Figure 17.212 Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.213 Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.214 Autoinjectors Market for Other Indications in North America: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.215 Autoinjectors Market for Other Indications in Europe, 2020-2030 (USD Million)
Figure 17.216 Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.217 Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.218 Autoinjectors Market for Other Indications in Europe: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.219 Autoinjectors Market for Other Indications in Asia Pacific, 2020-2030 (USD Million)
Figure 17.220 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.221 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.222 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.223 Autoinjectors Market for Other Indications in Rest of the World, 2020-2030 (USD Million)
Figure 17.224 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2020-2030 (USD Million)
Figure 17.225 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2020-2030 (USD Million)
Figure 17.226 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Type of Molecule, 2020-2030 (USD Million)
Figure 17.227 Global Autoinjectors Market for Other Indications, 2020-2030 (Units, Million)
Figure 17.228 Autoinjectors Market for Other Indications in North America, 2020-2030 (Units, Million)
Figure 17.229 Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.230 Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.231 Autoinjectors Market for Other Indications in North America: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.232 Autoinjectors Market for Other Indications in Europe, 2020-2030 (Units, Million)
Figure 17.233 Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.234 Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.235 Autoinjectors Market for Other Indications in Europe: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.236 Autoinjectors Market for Other Indications in Asia Pacific, 2020-2030 (Units, Million)
Figure 17.237 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.238 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.239 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Type of Molecule, 2020-2030 (Units, Million)
Figure 17.240 Autoinjectors Market for Other Indications in Rest of the World, 2020-2030 (Units, Million)
Figure 17.241 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2020-2030 (Units, Million)
Figure 17.242 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2020-2030 (Units, Million)
Figure 17.243 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Type of Molecule, 2020-2030 (Units, Million)

List Of  Tables 

Table 3.1 Comparison of Self-Injection Devices
Table 3.2 Benefits of Autoinjectors
Table 4.1 Cartridge Manufacturers
Table 4.2 Glass Prefilled Syringes Available in the Market
Table 4.3 Plastic Prefilled Syringes Available in the Market
Table 4.4 Vials Available in the Market
Table 4.5 Comparison of Fabrication Material Used for Primary Drug Containers
Table 5.1 Autoinjectors: List of Devices
Table 5.2 Autoinjectors: List of Developers
Table 8.1 Patent Portfolio: CPC Symbols
Table 8.2 Patent Portfolio: Most Popular CPC Symbols
Table 8.3 Patent Portfolio: List of Top CPC Symbols
Table 8.4 Patent Valuation Analysis: Categorization based on Proprietary Scoring Criteria
Table 8.5 Patent Portfolio: List of Relatively Higher Value Patents
Table 9.1 Autoinjector Combination Products: List of Approved Drugs
Table 9.2 Autoinjector Combination Products: List of Pipeline Drugs
Table 9.3 Autoinjector Combination Products: List of Developers
Table 10.1 Autoinjector-based Combination Products Available / Under Evaluation
Table 10.2 Adrenaline: Commercially Available Autoinjectors
Table 10.3 Adrenaline: Other Formulations
Table 10.4 Interferon β-1a Autoinjectors
Table 10.5 Interferon β-1b Autoinjectors
Table 10.6 Interferon-β Drugs: Other Dosage Forms
Table 10.7 Migraine: Commercially Available Autoinjectors
Table 10.8 Sumatriptan Succinate: Other Formulations
Table 10.9 Rheumatoid Arthritis: Commercially Available Autoinjectors
Table 11.1 Marketed Molecules: Most Likely Drug Candidates
Table 11.2 Marketed Molecules: Likely Drug Candidates
Table 11.3 Marketed Molecules: Less Likely Drug Candidates
Table 11.4 Marketed Molecules: Unlikely Drug Candidates
Table 11.5 Pipeline Molecules: Most Likely Drug Candidates
Table 11.6 Pipeline Molecules: Likely Drug Candidates
Table 11.7 Pipeline Molecules: Less Likely Drug Candidates
Table 11.8 Pipeline Molecules: Unlikely Drug Candidates
Table 12.1 Antares Pharma: Recent Developments and Future Outlook
Table 12.2 Consort Medical: Recent Developments and Future Outlook
Table 12.3 DALI Medical Devices: Recent Developments and Future Outlook
Table 12.4 Elcam Medical: Comparison of Autoinjectors
Table 12.5 Elcam Medical: Recent Developments and Future Outlook
Table 12.6 Jiangsu Delfu: Autoinjectors
Table 12.7 Delfu Autoinjectors: Specifications
Table 12.8 Oval Medical Technologies: Recent Developments and Future Outlook
Table 12.9 Owen Mumford: Comparison of Autoinjectors
Table 12.10 Owen Mumford: Recent Developments and Future Outlook
Table 12.11 SHL: Comparison of Two-Step Disposable Autoinjectors
Table 12.12 SHL: Comparison of Three-Step Disposable Autoinjectors
Table 12.13 SHL Group: Recent Developments and Future Outlook
Table 12.14 Union Medico: Comparison of 45˚ Autoinjectors
Table 12.15 Union Medico: Comparison of 90˚ Autoinjectors
Table 12.16 Ypsomed: Comparison of Autoinjectors
Table 12.17 Ypsomed: Recent Developments and Future Outlook
Table 13.1 AktiVax: Company Details
Table 13.2 Amneal Pharmaceuticals: Company Details
Table 13.3 kaléo: Company Details
Table 13.4 MiniEpi: Company Details
Table 13.5 Nemera: Company Details
Table 13.6 Nuance Designs: Company Details
Table 13.7 Windgap Medical: Company Details
Table 13.8 Xeris Pharmaceuticals: Company Details
Table 13.9 Zion Clinical Pharmacy: Company Details
Table 14.1 KOL Analysis: List of Principal Investigators / Sub-Investigators / Study Directors
Table 14.2 KOL Analysis: Number of Publications and Citations
Table 14.3 KOL Analysis: List of Patents Applicants
Table 14.4 KOL Analysis: Number of Affiliations, LinkedIn Connections and Years of Experience
Table 16.1 List of Medical Device CMOs Offering Services for Drug Delivery Devices
Table 16.2 Medical Device CMOs Offering Services for Drug Delivery Devices: Information on Production Services
Table 18.1 Conclusion: Key Takeaways
Table 19.1 PHC: Company Snapshot
Table 19.2 Elcam Medical: Company Snapshot
Table 19.3 DALI Medical Devices: Company Snapshot
Table 20.1 Autoinjectors: Distribution by Usability
Table 20.2 Autoinjectors: Distribution by Type of Primary Container
Table 20.3 Autoinjectors: Distribution by Volume of Container
Table 20.4 Autoinjectors: Distribution by Type of Dose
Table 20.5 Autoinjectors: Distribution by Route of Administration
Table 20.6 Autoinjectors: Distribution by Actuation Mechanism
Table 20.7 Autoinjectors: Distribution by Type of Feedback System
Table 20.8 Autoinjector Device Developers: Distribution by Year of Establishment
Table 20.9 Autoinjector Device Developers: Distribution by Company Size
Table 20.10 Autoinjector Device Developers: Distribution by Geographical Location of Headquarters
Table 20.11 Autoinjector Device Developers: Distribution by Geographical Location of Manufacturing Facilities
Table 20.12 Patent Portfolio: Distribution by Type of Patent
Table 20.13 Patent Portfolio: Cumulative Distribution by Application Year
Table 20.14 Patent Portfolio: Year-wise Distribution by Application Year
Table 20.15 Patent Portfolio: Distribution by Issuing Authority
Table 20.16 Patent Portfolio: Distribution by CPC Symbols
Table 20.17 Leading Players: Distribution by Number of Patents
Table 20.18 Patent Portfolio: Distribution of Patents by Geography and Type
Table 20.19 Patent Portfolio: Age of Patents
Table 20.20 Patent Portfolio: Valuation Analysis
Table 20.21 Approved Autoinjector Combination Products: Distribution by Initial year of Approval
Table 20.22 Approved Autoinjector Combination Products: Distribution by Usability of Product
Table 20.23 Approved Autoinjector Combination Products: Distribution by Route of Administration
Table 20.24 Approved Autoinjector Combination Products: Distribution by Type of Molecule
Table 20.25 Approved Autoinjector Combination Products: Distribution by Dose Strength
Table 20.26 Approved Autoinjector Combination Products: Distribution by Therapeutic Area
Table 20.27 Approved Autoinjector Combination Products: Distribution by Other Approved Dosage Forms
Table 20.28 Pipeline Autoinjector Combination Products: Distribution by Phase of Development
Table 20.29 Pipeline Autoinjector Combination Products: Distribution by Route of Administration
Table 20.30 Pipeline Autoinjector Combination Products: Distribution by Type of Molecule
Table 20.31 Pipeline Autoinjector Combination Products: Distribution by Therapeutic Area
Table 20.32 Autoinjector Combination Product Developers: Distribution by Year of Establishment
Table 20.33 Autoinjector Combination Product Developers: Distribution by Company Size
Table 20.34 Autoinjector Combination Product Developers: Distribution by Geographical Location of Headquarters
Table 20.35 EpiPen: Historical Drug Sales (USD Billion), 2012-2017
Table 20.36 Interferon β-1a: Historical Sales (USD Billion), 2014-H1 2019
Table 20.37 Interferon β-1b: Historical Sales (USD Million), 2014-H1 2019
Table 20.38 Migraine: Historical Drug Sales (USD Million), 2014-H1 2019
Table 20.39 Rheumatoid Arthritis: Historical Drug Sales (USD Billion), 2014-H1 2019
Table 20.40 Antares Pharma: Annual Revenues, 2014-H1 2019 (USD Million)
Table 20.41 Consort Medical: Annual Revenues, FY 13/14-FY 18/19 (GBP Million)
Table 20.42 Ypsomed: Annual Revenues, FY 14/15-FY 18/19 (CHF Million)
Table 20.43 Ypsomed: Sales by Business Divisions, FY 18/19 (CHF Million, %)
Table 20.44 Global Autoinjectors Market, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.45 Global Autoinjectors Market: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.46 Global Autoinjectors Market: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.47 Global Autoinjectors Market: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.48 Autoinjectors Market in North America, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.49 Autoinjectors Market in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.50 Autoinjectors Market in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.51 Autoinjectors Market in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.52 Autoinjectors Market in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.53 Autoinjectors Market in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.54 Autoinjectors Market in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.55 Autoinjectors Market in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.56 Autoinjectors Market in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.57 Autoinjectors Market in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.58 Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.59 Autoinjectors Market in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.60 Autoinjectors Market in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.61 Autoinjectors Market in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.62 Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.63 Autoinjectors Market in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.64 Global Autoinjectors Market, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.65 Global Autoinjectors Market: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.66 Global Autoinjectors Market: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.67 Global Autoinjectors Market: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.68 Autoinjectors Market in North America, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.69 Autoinjectors Market in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.70 Autoinjectors Market in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.71 Autoinjectors Market in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.72 Autoinjectors Market in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.73 Autoinjectors Market in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.74 Autoinjectors Market in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.75 Autoinjectors Market in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.76 Autoinjectors Market in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.77 Autoinjectors Market in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.78 Autoinjectors Market in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.79 Autoinjectors Market in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.80 Autoinjectors Market in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.81 Autoinjectors Market in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.82 Autoinjectors Market in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.83 Autoinjectors Market in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.84 Global Autoinjectors Market for Anaphylaxis, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.85 Autoinjectors Market for Anaphylaxis in North America, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.86 Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.87 Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.88 Autoinjectors Market for Anaphylaxis in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.89 Autoinjectors Market for Anaphylaxis in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.90 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.91 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.92 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.93 Autoinjectors Market for Anaphylaxis in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.94 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.95 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.96 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.97 Autoinjectors Market for Anaphylaxis in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.98 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.99 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.100 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.101 Global Autoinjectors Market for Anaphylaxis, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.102 Autoinjectors Market for Anaphylaxis in North America, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.103 Autoinjectors Market for Anaphylaxis in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.104 Autoinjectors Market for Anaphylaxis in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.105 Autoinjectors Market for Anaphylaxis in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.106 Autoinjectors Market for Anaphylaxis in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.107 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.108 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.109 Autoinjectors Market for Anaphylaxis in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.110 Autoinjectors Market for Anaphylaxis in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.111 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.112 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.113 Autoinjectors Market for Anaphylaxis in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.114 Autoinjectors Market for Anaphylaxis in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.115 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.116 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.117 Autoinjectors Market for Anaphylaxis in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.118 Global Autoinjectors Market for Multiple Sclerosis, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.119 Autoinjectors Market for Multiple Sclerosis in North America, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.120 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.121 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.122 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.123 Autoinjectors Market for Multiple Sclerosis in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.124 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.125 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.126 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.127 Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.128 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.129 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.130 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.131 Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.132 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.133 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.134 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.135 Global Autoinjectors Market for Multiple Sclerosis, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.136 Autoinjectors Market for Multiple Sclerosis in North America, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.137 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.138 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.139 Autoinjectors Market for Multiple Sclerosis in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.140 Autoinjectors Market for Multiple Sclerosis in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.141 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.142 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.143 Autoinjectors Market for Multiple Sclerosis in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.144 Autoinjectors Market for Multiple Sclerosis in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.145 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.146 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.147 Autoinjectors Market for Multiple Sclerosis in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.148 Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.149 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.150 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.151 Autoinjectors Market for Multiple Sclerosis in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.152 Global Autoinjectors Market for Rheumatoid Arthritis, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.153 Autoinjectors Market for Rheumatoid Arthritis in North America, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.154 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.155 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.156 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.157 Autoinjectors Market for Rheumatoid Arthritis in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.158 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.159 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.160 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.161 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.162 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.163 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.164 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.165 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.166 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.167 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.168 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.169 Global Autoinjectors Market for Rheumatoid Arthritis, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.170 Autoinjectors Market for Rheumatoid Arthritis in North America, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.171 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.172 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.173 Autoinjectors Market for Rheumatoid Arthritis in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.174 Autoinjectors Market for Rheumatoid Arthritis in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.175 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.176 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.177 Autoinjectors Market for Rheumatoid Arthritis in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.178 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.179 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.180 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.181 Autoinjectors Market for Rheumatoid Arthritis in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.182 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.183 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.184 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.185 Autoinjectors Market for Rheumatoid Arthritis in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.186 Global Autoinjectors Market for Migraine, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.187 Autoinjectors Market for Migraine in North America, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.188 Autoinjectors Market for Migraine in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.189 Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.190 Autoinjectors Market for Migraine in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.191 Autoinjectors Market for Migraine in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.192 Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.193 Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.194 Autoinjectors Market for Migraine in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.195 Autoinjectors Market for Migraine in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.196 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.197 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.198 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.199 Autoinjectors Market for Migraine in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.200 Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.201 Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.202 Autoinjectors Market for Migraine in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.203 Global Autoinjectors Market for Migraine, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.204 Autoinjectors Market for Migraine in North America, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.205 Autoinjectors Market for Migraine in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.206 Autoinjectors Market for Migraine in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.207 Autoinjectors Market for Migraine in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.208 Autoinjectors Market for Migraine in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.209 Autoinjectors Market for Migraine in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.210 Autoinjectors Market for Migraine in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.211 Autoinjectors Market for Migraine in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.212 Autoinjectors Market for Migraine in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.213 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.214 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.215 Autoinjectors Market for Migraine in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.216 Autoinjectors Market for Migraine in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.217 Autoinjectors Market for Migraine in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.218 Autoinjectors Market for Migraine in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.219 Autoinjectors Market for Migraine in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.220 Global Autoinjectors Market for Diabetes, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.221 Autoinjectors Market for Diabetes in North America, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.222 Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.223 Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.224 Autoinjectors Market for Diabetes in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.225 Autoinjectors Market for Diabetes in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.226 Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.227 Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.228 Autoinjectors Market for Diabetes in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.229 Autoinjectors Market for Diabetes in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.230 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.231 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.232 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.233 Autoinjectors Market for Diabetes in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.234 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.235 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.236 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.237 Global Autoinjectors Market for Diabetes, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.238 Autoinjectors Market for Diabetes in North America, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.239 Autoinjectors Market for Diabetes in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.240 Autoinjectors Market for Diabetes in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.241 Autoinjectors Market for Diabetes in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.242 Autoinjectors Market for Diabetes in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.243 Autoinjectors Market for Diabetes in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.244 Autoinjectors Market for Diabetes in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.245 Autoinjectors Market for Diabetes in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.246 Autoinjectors Market for Diabetes in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.247 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.248 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.249 Autoinjectors Market for Diabetes in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.250 Autoinjectors Market for Diabetes in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.251 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.252 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.253 Autoinjectors Market for Diabetes in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.254 Global Autoinjectors Market for Other Indications, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.255 Autoinjectors Market for Other Indications in North America, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.256 Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.257 Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.258 Autoinjectors Market for Other Indications in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.259 Autoinjectors Market for Other Indications in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.260 Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.261 Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.262 Autoinjectors Market for Other Indications in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.263 Autoinjectors Market for Other Indications in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.264 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.265 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.266 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.267 Autoinjectors Market for Other Indications in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.268 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.269 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.270 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 20.271 Global Autoinjectors Market for Other Indications, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.272 Autoinjectors Market for Other Indications in North America, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.273 Autoinjectors Market for Other Indications in North America: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.274 Autoinjectors Market for Other Indications in North America: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.275 Autoinjectors Market for Other Indications in North America: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.276 Autoinjectors Market for Other Indications in Europe, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.277 Autoinjectors Market for Other Indications in Europe: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.278 Autoinjectors Market for Other Indications in Europe: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.279 Autoinjectors Market for Other Indications in Europe: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.280 Autoinjectors Market for Other Indications in Asia Pacific, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.281 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.282 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.283 Autoinjectors Market for Other Indications in Asia Pacific: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.284 Autoinjectors Market for Other Indications in Rest of the World, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.285 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Usability, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.286 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Route of Administration, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)
Table 20.287 Autoinjectors Market for Other Indications in Rest of the World: Distribution by Type of Molecule, 2020-2030, Conservative, Base and Optimistic Scenario (Units, Million)

Listed Companies

  1. AbbVie
  2. AktiVax
  3. ALK-Abelló
  4. Allergy Therapeutics
  5. Alvogen
  6. Alvotech 
  7. AMAG Pharmaceuticals
  8. AMETEK Engineered Medical Components
  9. Amgen
  10. Amneal Pharmaceuticals 
  11. Amsino
  12. Androsystems
  13. Antares Pharma
  14. Apex Medical Technologies
  15. Asahi Kasei Pharma
  16. Ascendis Pharma
  17. AstraZeneca
  18. Atrion
  19. B&A Health
  20. Bausch Health Companies 
  21. Bayer 
  22. BD
  23. Bespak
  24. BIOCORP LIFE SCIENCES
  25. Biogen 
  26. BioGene Pharmaceutical
  27. Biomerics
  28. Boehringer Ingelheim
  29. Bristol-Myers Squibb 
  30. Cambridge Consultants
  31. Canon Virginia
  32. Carclo
  33. Celltrion 
  34. ChemProtect 
  35. Chugai Pharmaceutical
  36. CinnaGen
  37. Cirtec Medical
  38. Consort Medical
  39. Contract Medical International
  40. Creare 
  41. Crossject
  42. Doctor Pack
  43. Donatelle
  44. Dr. Reddy's Laboratory
  45. DSM
  46. Duoject Medical Systems
  47. EA Pharma
  48. Eastek International
  49. EG-GILERO
  50. Eisai
  51. Elcam Drug Delivery Devices
  52. Eli Lilly
  53. EMD Serono
  54. Europlaz Technologies
  55. Evergreen Research
  56. Fabrico Medical
  57. Ferring Pharmaceuticals 
  58. Flex
  59. Forefront Medical Technology
  60. Fresenius Kabi
  61. Freudenberg Medical
  62. Fujifilm Kyowa Kirin Biologics
  63. Genentech
  64. Gerresheimer
  65. GlaxoSmithKline
  66. GW Plastics
  67. H&T Presspart
  68. Haselmeier 
  69. Haywood Vocational Opportunities
  70. Hoffmann-La Roche 
  71. IEC Electronics
  72. Immunex
  73. Integer
  74. Interplex
  75. Inzign
  76. Jabil
  77. Janssen Biotech
  78. JCR Pharmaceuticals
  79. Jiangsu Delfu medical device
  80. Kaléo
  81. King Pharmaceuticals
  82. Lincoln Medical Centre
  83. Lineage Therapeutics
  84. Lupin
  85. M&M Qualtech
  86. Mack Molding
  87. Medac Pharma
  88. Medeca Pharma
  89. Medicom Innovation Partner
  90. Merck
  91. Meridian Medical Technologies
  92. Midwest Interventional Systems
  93. MiniEpi
  94. Modulus
  95. Momenta Pharmaceuticals
  96. Mylan
  97. NACS
  98. Natech Plastics
  99. Nemera
  100. NeoTech Medical
  101. Nexeon MedSystems
  102. Novartis
  103. Nuance Designs 
  104. Occam Design
  105. Ology Bioservices
  106. Oval Medical Technologies
  107. Owen Mumford
  108. P3 Medical
  109. PA Consulting Group
  110. Palatin Technologies
  111. Paramit
  112. Peridot
  113. Pfizer
  114. Pharma Tech
  115. PHC Injection Device Technologies
  116. Phillips-Medisize
  117. Plastikon
  118. Plexus
  119. Polyzen
  120. Precision Engineered Products
  121. Precision MicroFab
  122. Preco
  123. Pro-Dex
  124. Promius Pharma
  125. Proven Process Medical Devices
  126. Providence Enterprise
  127. Quality Tech Services
  128. Rafa Laboratories
  129. RaviMed
  130. Regeneron Pharmaceuticals
  131. Riverside Medical Packaging
  132. Roche 
  133. Röchling Medical
  134. Samsung Bioepis
  135. SanaVita Medical
  136. Sandoz
  137. Sanmina
  138. Sanofi
  139. Shire
  140. SHL Group
  141. SMC
  142. Sovrin Plastics
  143. Stellartech Research
  144. SteriPack
  145. Stevanato Group
  146. Sumitomo Dainippon Pharma
  147. Sun Pharmaceutical
  148. Survival Technologies 
  149. Switchback Medical
  150. Takeda Pharmaceutical
  151. Teva Pharmaceutical
  152. Trelleborg Sealing Solutions
  153. Trend Technologies
  154. TRICOR Systems
  155. UCB Biopharma
  156. Uman Pharma
  157. Union Medico
  158. US WorldMeds
  159. Valtronic
  160. VascuTech Medical
  161. Vaupell
  162. ViVO Smart Medical Devices
  163. West Pharmaceutical Services
  164. Westmed
  165. Windgap Medical
  166. Xeris Pharmaceuticals
  167. YL Biologics 
  168. Ypsomed
  169. Zenius
  170. Zion Clinic Pharmacy

Segmentation

The USD 1.5 billion (by 2030) financial opportunity within the autoinjector devices market has been analyzed across the following segments:

  • Usability
    • Disposable 
    • Reusable
  • Route of administration 
    • Subcutaneous
    • Intramuscular
  • Type of molecule 
    • Antibody
    • Peptide
    • Protein
    • Small molecule
  • Therapeutic indication
    • Anaphylaxis
    • Diabetes 
    • Migraine 
    • Multiple sclerosis
    • Rheumatoid arthritis
    • Other indications
  • Key geographical regions 
    • North America
    • Europe
    • Asia-Pacific
    • Rest of the World

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com